Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Cancer
Interventions: Dabrafenib, Trametinib, Panitumumab, 5-fluorouracil; Drug · Device
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 8
States / cities: Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more

Conditions: Asthma
Interventions: PACE, PACE Plus; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: Up to 99 Years
Enrollment: 1,176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Rett Syndrome
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 3 Years to 18 Years · Female only
Enrollment: 146 participants
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Neurogenic Bladder, Multiple Sclerosis, Voiding Dysfunction
Interventions: Transcranial Rotating Permanent Magnet Stimulator (TRPMS); Device
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions: Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more

Conditions: Dentin Sensitivity, Oral Hygiene
Interventions: Test Dentifrice, Reference Dentifrice (Aquafresh Cavity Protection); Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Cystic Fibrosis
Interventions: lumacaftor, ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Mars Cocoa Extract Capsules; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 30 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Davis, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: BIIB105, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Palo Alto, California + 11 more

Conditions: Healthy Participants
Interventions: TAK-510, TAK-510 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Blood Pressure, Orthostatic Hypotension, Vascular Diseases
Interventions: Blueberry Consumption, Dried Date Consumption; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 70 Years to 100 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Brookline, Massachusetts • Dedham, Massachusetts

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Los Angeles, California • Cincinnati, Ohio

Conditions: Influenza
Interventions: mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only, mRNA-1018 for H7 Only, mRNA-1018 for H5 Only-CG; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Hollywood, Florida • Savannah, Georgia • Lenexa, Kansas + 6 more

Conditions: HER2-expressing Cancers
Interventions: ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more

Conditions: Vaginal Vault Prolapse, Post-Hysterectomy Vaginal Vault Prolapse, Prolapse, Vaginal
Interventions: Intraperitoneal Uterosacral Ligament Suspension, Extraperitoneal Uterosacral Ligament Suspension; Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain
Interventions: WHT; Other
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: New Imaging Modality
Interventions: 3D Sonography analysis; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: TAK-951, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: NX-5948; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Duarte, California • San Francisco, California • Denver, Colorado + 15 more

Conditions: Cancer
Interventions: SRK-181, anti-PD-(L)1 antibody therapy; Biological
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Fullerton, California • La Jolla, California • Los Angeles, California + 14 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer, c-MET
Interventions: Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 18
States / cities: Chandler, Arizona • Duarte, California • Irvine, California + 15 more

Conditions: Actinic Keratoses
Interventions: ingenol mebutate 0.015%, dermasil lotion; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Cancer
Interventions: LY3007113; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Santa Monica, California • San Antonio, Texas

Conditions: Healthy Volunteers, Sjögren's Syndrome
Interventions: ASP5502, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

Improving Asthma Outcomes Through Cultural Competence Training for Physicians

Development of a Behavioral Outcome Measure for Rett Syndrome (RettBe)

Brain Targets in Patients With Bladder Emptying Difficulties

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 1

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

A Study of TAK-510 in Healthy Adults

Effects of Blueberries in Older Adults

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Intraperitoneal and Extraperitoneal Uterosacral Ligament Suspensions for Post-Hysterectomy Vaginal Vault Prolapse

Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System

3 Dimensional Sonography Imaging

A Study of TAK-951 in Healthy Adults

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Treatment of Actinic Keratoses (AK) on the Face

A Study of LY3007113 in Participants With Advanced Cancer

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome